ASX 200 healthcare share sinks on $2 billion asset sale

Investors are pressuring the healthcare share amid news of a major hospital sale.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

S&P/ASX 200 Index (ASX: XJO) healthcare share Ramsay Health Care Ltd (ASX: RHC) is slipping today.

The healthcare stock closed on Friday trading for $53.93 a share. In early trade on Monday, shares are swapping hands for $53.35, down 1.08%.

For some context, the ASX 200 is down 0.19% at this same time.

This comes following news of a multi-billion-dollar hospital asset sale.

What did the ASX 200 healthcare share announce?

ASX 200 investors are pressuring the healthcare share after the company reported it has reached an agreement – together with its partner Sime Darby Holdings Berhad – to sell its 50:50 joint venture in Asia, Ramsay Sime Darby Health Care.

Columbia Asia Healthcare will pay MYR6.06 billion (approximately AU$2 billion) for hospital assets, representing 100% of the joint venture's enterprise value.

Ramsay said it expects to achieve a net profit after tax (NPAT) for its share of the joint venture of around $630 million. This will be reflected in the company's FY 2024 full-year results through the "discontinued operations line".

Management expects pre-tax (post-transaction cost) proceeds of around $935 million. The ASX 200 healthcare share will use the funds to pay down debt. This is expected to result in annualised interest cost savings of $55 million.

FY 2024 net interest costs (including AASB16 lease costs) are now expected to be at the lower end of Ramsay's previously guided range of $570 million to $600 million.

Commenting on the asset sale, Sime Darby CEO Jeffri Salim Davidson said, "While the hospital business is a great asset … the offer from Columbia Asia was one we could not refuse."

Subject to the receipt of regulatory approval from Australia's Foreign Investment Review Board, the sale is expected to be completed by the end of 3Q FY 2024.

Ramsay Health Care share price snapshot

Up 7% over the past month, the ASX 200 healthcare share remains down almost 13% over the past full year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »